[
  {
    "ts": null,
    "headline": "Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?",
    "summary": "Once up and running, it and other projects should make the company's supply chain stronger.",
    "url": "https://finnhub.io/api/news?id=8cf6386dfee6bed163a4014ccea9ca11991ef169a385ea7819f2cea7023e1f7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758746678,
      "headline": "Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?",
      "id": 136865981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Once up and running, it and other projects should make the company's supply chain stronger.",
      "url": "https://finnhub.io/api/news?id=8cf6386dfee6bed163a4014ccea9ca11991ef169a385ea7819f2cea7023e1f7f"
    }
  },
  {
    "ts": null,
    "headline": "Podcast: How oral GLP-1RAs are set to impact the obesity market",
    "summary": "As Eli Lilly and Novo Nordisk await approval of their oral GLP-1RAs, the healthcare editorial team discuss data and market opportunity.",
    "url": "https://finnhub.io/api/news?id=9afa70e828c131f3f4f9f69966c58ab74c940a851bd8641457a95baa571f12ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758735806,
      "headline": "Podcast: How oral GLP-1RAs are set to impact the obesity market",
      "id": 136865982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As Eli Lilly and Novo Nordisk await approval of their oral GLP-1RAs, the healthcare editorial team discuss data and market opportunity.",
      "url": "https://finnhub.io/api/news?id=9afa70e828c131f3f4f9f69966c58ab74c940a851bd8641457a95baa571f12ef"
    }
  },
  {
    "ts": null,
    "headline": "LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?",
    "summary": "Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.",
    "url": "https://finnhub.io/api/news?id=07331e108658c7db68779258eaf6906b842da0469b7e09acd3da1b6bc104f606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758731100,
      "headline": "LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?",
      "id": 136865983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.",
      "url": "https://finnhub.io/api/news?id=07331e108658c7db68779258eaf6906b842da0469b7e09acd3da1b6bc104f606"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to build $6.5B Houston factory for its first obesity pill",
    "summary": "The pharmaceutical giant’s expansion into Texas will create 615 full-time jobs and receive $5.5 million in state funding.",
    "url": "https://finnhub.io/api/news?id=ec89b5bde8fd06d2cdcebbd344f3c774fe25daf187eb7dde6d8c2595ede3ee1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758715980,
      "headline": "Lilly to build $6.5B Houston factory for its first obesity pill",
      "id": 136865984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical giant’s expansion into Texas will create 615 full-time jobs and receive $5.5 million in state funding.",
      "url": "https://finnhub.io/api/news?id=ec89b5bde8fd06d2cdcebbd344f3c774fe25daf187eb7dde6d8c2595ede3ee1d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to build $6.5bn orforglipron production site in Texas",
    "summary": "The API facility is part of Eli Lilly’s $27bn US manufacturing drive.",
    "url": "https://finnhub.io/api/news?id=ffe4249466168ff87aeba6c5a010eb611b325973c3013a48fef93014695ef56e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758714048,
      "headline": "Eli Lilly to build $6.5bn orforglipron production site in Texas",
      "id": 136861532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The API facility is part of Eli Lilly’s $27bn US manufacturing drive.",
      "url": "https://finnhub.io/api/news?id=ffe4249466168ff87aeba6c5a010eb611b325973c3013a48fef93014695ef56e"
    }
  },
  {
    "ts": null,
    "headline": "How Will Eli Lilly’s Mounjaro Trial Results Shape Its 2025 Valuation?",
    "summary": "If you have been keeping an eye on Eli Lilly’s stock, you are not alone, and you are probably wondering if now is the right moment to make your move. The last five years have been nothing short of remarkable, with shares surging over 440.2%. While few stocks can boast that kind of long-term growth, the road lately has had more bumps. The stock is down 2.3% in the last week and remains almost 19% below where it stood a year ago. However, over the last month, investors have gotten a bit of...",
    "url": "https://finnhub.io/api/news?id=752390bb5bf659eda2c46f71776f8b91ae8ba3f74aa66ea22c4a26a2bce3318b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758713943,
      "headline": "How Will Eli Lilly’s Mounjaro Trial Results Shape Its 2025 Valuation?",
      "id": 136861533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If you have been keeping an eye on Eli Lilly’s stock, you are not alone, and you are probably wondering if now is the right moment to make your move. The last five years have been nothing short of remarkable, with shares surging over 440.2%. While few stocks can boast that kind of long-term growth, the road lately has had more bumps. The stock is down 2.3% in the last week and remains almost 19% below where it stood a year ago. However, over the last month, investors have gotten a bit of...",
      "url": "https://finnhub.io/api/news?id=752390bb5bf659eda2c46f71776f8b91ae8ba3f74aa66ea22c4a26a2bce3318b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
    "summary": "Amgen: Imdelltra Could Be The Next Game Changer",
    "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758709050,
      "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
      "id": 136861111,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement",
    "summary": "Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.",
    "url": "https://finnhub.io/api/news?id=763acbef2606099f6dcd9cf334444d92c997c2c0a2f7d0896c192e7cc2ee1a09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758705000,
      "headline": "The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement",
      "id": 136861433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.",
      "url": "https://finnhub.io/api/news?id=763acbef2606099f6dcd9cf334444d92c997c2c0a2f7d0896c192e7cc2ee1a09"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to invest $6.5bn in API manufacturing facility in Texas",
    "summary": "The Houston facility is the company’s eighth US manufacturing site announced since 2020.",
    "url": "https://finnhub.io/api/news?id=228b5e8e8905a59a2197f772212b32d6ffeb271b7a785dae85352fdc293010dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758703169,
      "headline": "Lilly to invest $6.5bn in API manufacturing facility in Texas",
      "id": 136861535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Houston facility is the company’s eighth US manufacturing site announced since 2020.",
      "url": "https://finnhub.io/api/news?id=228b5e8e8905a59a2197f772212b32d6ffeb271b7a785dae85352fdc293010dc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's boss calls UK the 'worst' European country for drug prices",
    "summary": "LONDON (Reuters) -Eli Lilly Chief Executive Dave Ricks said Britain was \"probably the worst country in Europe\" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.  The remarks are part of a broader backlash from pharmaceutical giants, including Merck and AstraZeneca, who have paused or scaled back investments in Britain over the challenging environment.  Ricks said Britain would miss out on new drugs if it did not raise prices and scrap a rebate scheme which requires companies to contribute a portion of their UK drug revenue to the state-run NHS.",
    "url": "https://finnhub.io/api/news?id=299e5d1ae0fcaa078a7352e2f66df3c7435c3b5b79781559c07c82aaaa04bb76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758701500,
      "headline": "Eli Lilly's boss calls UK the 'worst' European country for drug prices",
      "id": 136861536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -Eli Lilly Chief Executive Dave Ricks said Britain was \"probably the worst country in Europe\" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.  The remarks are part of a broader backlash from pharmaceutical giants, including Merck and AstraZeneca, who have paused or scaled back investments in Britain over the challenging environment.  Ricks said Britain would miss out on new drugs if it did not raise prices and scrap a rebate scheme which requires companies to contribute a portion of their UK drug revenue to the state-run NHS.",
      "url": "https://finnhub.io/api/news?id=299e5d1ae0fcaa078a7352e2f66df3c7435c3b5b79781559c07c82aaaa04bb76"
    }
  }
]